高级检索
当前位置: 首页 > 详情页

Efficacy of Qingre Huayu Fang on atherosclerotic vulnerable plaque in apolipoprotein E knockout mice: proteasome pathway involvement

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE ◇ CSCD-C ◇ 卓越:梯队期刊

单位: [1]Department of Cardiology, Guizhou Provincial People's Hospital, Guiyang 520000, China [2]Department of Hypertension,Beijing An-zhen Hospital, Beijing 100029,China [3]Institute of Clinical Medicine, Bei-jing China-Japan Friendship Hospital,Beijing 100029,China [4]Emergency Department, Guizhou Provincial People's Hospital,Guiyang 520000, China
出处:
ISSN:

关键词: atherosclerosis plaque atherosclerotic proteasome endopeptidase complex CD40 ligand NF-kappa B Qingre Huayu

摘要:
OBJECTIVE: To investigate the efficacy and mechanism of the Qingre Huayu Fang on atherosclerotic vulnerable plaque in apolipoprotein E (ApoE) knockout mice through the ubiquitin proteasome pathway. METHODS: Sixty 8-week-old C57BL/6J ApoE knockout mice were fed a high-fat for 12 weeks and randomly divided into four treatment groups (n = 15 each): high-fat control, bortezomib (a proteasome inhibitor), bortezomib combined with Qingre Hua-yu Fang, and Qingre Huayu Fang alone. Aortic sections were examined for plaque development, inflammatory cell infiltration, type I / III collagen expression and immunohistochemical staining of CD40L, nuclear factor-kappa B (NF-kappa B)/P65 and ubiquitin. RESULTS: Mice in the high-fat control group had obvious atherosclerosis, with increased aortic plaque area. The degree of atherosclerosis of the atherosclerotic plaque was reduced in all of the treatment groups that received bortezomib and/or Duzhong (Cortex Eucommiae) Qingre Huayu. The expression of NF-.B, CD40L and ubiquitin were all reduced in the group that received combination bortezomib + Qingre Huayu Fang. CONCLUSION: The Qingre Huayu Fang inhibited aortic atherosclerosis in mice through a mechanism that may involve inhibition of the ubiquitin proteasome pathway. (C) 2021 JTCM. All rights reserved.

基金:
语种:
WOS:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 4 区 医学
小类 | 4 区 全科医学与补充医学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 全科医学与补充医学
JCR分区:
出版当年[2019]版:
Q4 INTEGRATIVE & COMPLEMENTARY MEDICINE
最新[2023]版:
Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2019版] 出版当年五年平均[2015-2019] 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者单位: [1]Department of Cardiology, Guizhou Provincial People's Hospital, Guiyang 520000, China
通讯作者:
通讯机构: [2]Department of Hypertension,Beijing An-zhen Hospital, Beijing 100029,China [*1]Department of Hypertension,Beijing Anzhen Hospital,Beijing 100029,China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:817 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)